Risk That Research and Development Will Not Be Commercialized or Monetized
First written in FY2016. 16 of 18 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2026: 14 of 29 companies on the "Worse" side.
74 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Such research and development will require substantial expenditures and time, but there is no guarantee that it will successfully be commercialized. Even if commercialization is successful, there is no guarantee that it will generate the expected returns.」
The uncertainty surrounding the expenditures and time required, commercialization and monetization of research and development into antifatigue products, femtech, functional materials and other areas continues to be disclosed. - FY2024WorsenedAnnual report
「Such research and development will require substantial expenditures and time, but there is no guarantee that it will successfully be commercialized. Even if commercialization is successful, there is no guarantee that it will generate the expected returns. Although the Company will pay close attention to profitability when selecting target fields, planning products and making research and development expenditures, research and development costs may increase in the future as the business is diversified and research areas expanded, which may affect the operating performance of our group.」
Against a backdrop of business diversification and expansion of research areas, including into antifatigue products and femtech, the disclosure more specifically describes the increase in research and development costs and the uncertainty surrounding commercialization and monetization. - FY2024-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is disclosed as having no material changes. - FY2024-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is disclosed as having no material changes. - FY2023RestatedAnnual report
「Such research and development will require substantial expenditures and time, but there is no guarantee that it will successfully be commercialized. Even if commercialization is successful, there is no guarantee that it will generate the expected returns.」
The uncertainty surrounding commercialization and monetization associated with research and development of biomarkers, foods, cosmetics, functional materials, pharmaceuticals and other products continues to be disclosed. - FY2023-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is disclosed as having no material changes. - FY2023-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is disclosed as having no material changes. - FY2022-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is disclosed as having no material changes. - FY2021-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is disclosed as having no material changes. - FY2021-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is disclosed as having no material changes. - FY2020RestatedAnnual report
「Such research and development will require substantial expenditures and time, but there is no guarantee that it will successfully be commercialized. Even if commercialization is successful, there is no guarantee that it will generate the expected returns.」
The uncertainty surrounding commercialization and monetization associated with research and development of biomarkers, foods, cosmetics, functional materials and other products continues to be disclosed. - FY2020-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is disclosed as having no material changes. - FY2020-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is disclosed as having no material changes. - FY2019-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is collectively disclosed as having no material changes. - FY2019-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is collectively disclosed as having no material changes. - FY2019-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk of commercializing and monetizing research and development is collectively disclosed as having no material changes. - FY2018RestatedAnnual report
「Such research and development will require substantial expenditures and time, but there is no guarantee that it will successfully be commercialized. Even if commercialization is successful, there is no guarantee that it will generate the expected returns.」
The uncertainty surrounding commercialization and monetization associated with research and development of biomarkers, foods, cosmetics and other products continues to be disclosed. - FY2016First statedAnnual report
「Such research and development will require substantial expenditures and time, but there is no guarantee that it will successfully be commercialized. Even if commercialization is successful, there is no guarantee that it will generate the expected returns.」
The Company indicates that research and development of biomarkers, biological evaluation systems, foods, cosmetics and other products requires expenditures and time, and may not lead to commercialization or monetization.